How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns

被引：35
作者：
Mazepa, Marshall A. [1 ]
Masias, Camila [2 ]
Chaturvedi, Shruti [3 ]
机构：
[1] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[2] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, 720 Rutland Ave,Ross Res Bldg,Room 1025, Baltimore, MD 21205 USA
来源：
BLOOD | 2019年 / 134卷 / 05期
关键词：
THROMBOTIC THROMBOCYTOPENIC PURPURA; PLASMA-EXCHANGE; ANTIBODY DEPLETION; ADAMTS13; ACTIVITY; RITUXIMAB; MICROANGIOPATHIES; BORTEZOMIB; EXPERIENCE; REMISSION; SAFETY;
D O I：
10.1182/blood.2019000954
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.
引用
收藏
页码：415 / 420
页数：6
相关论文
共 40 条
  • [1] IMPROVED SURVIVAL IN THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC UREMIC SYNDROME - CLINICAL-EXPERIENCE IN 108 PATIENTS
    BELL, WR
    BRAINE, HG
    NESS, PM
    KICKLER, TS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) : 398 - 403
  • [2] Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
    Bendapudi, Pavan K.
    Hurwitz, Shelley
    Fry, Ashley
    Marques, Marisa B.
    Waldo, Stephen W.
    Li, Ang
    Sun, Lova
    Upadhyay, Vivek
    Hamdan, Ayad
    Brunner, Andrew M.
    Gansner, John M.
    Viswanathan, Srinivas
    Kaufman, Richard M.
    Uhl, Lynne
    Stowell, Christopher P.
    Dzik, Walter H.
    Makar, Robert S.
    [J]. LANCET HAEMATOLOGY, 2017, 4 (04): : E157 - E164
  • [3] Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center
    Benhamou, Y.
    Boelle, P-Y
    Baudin, B.
    Ederhy, S.
    Gras, J.
    Galicier, L.
    Azoulay, E.
    Provot, F.
    Maury, E.
    Pene, F.
    Mira, J. -P.
    Wynckel, A.
    Presne, C.
    Poullin, P.
    Halimi, J. -M.
    Delmas, Y.
    Kanouni, T.
    Seguin, A.
    Mousson, C.
    Servais, A.
    Bordessoule, D.
    Perez, P.
    Hamidou, M.
    Cohen, A.
    Veyradier, A.
    Coppo, P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (02) : 293 - 302
  • [4] Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
    Benhamou, Ygal
    Assie, Cyrielle
    Boelle, Pierre-Yves
    Buffet, Marc
    Grillberger, Rana
    Malot, Sandrine
    Wynckel, Alain
    Presne, Claire
    Choukroun, Gabriel
    Poullin, Pascale
    Provot, Francois
    Gruson, Didier
    Hamidou, Mohamed
    Bordessoule, Dominique
    Pourrat, Jacques
    Mira, Jean-Paul
    Le Guern, Veronique
    Pouteil-Noble, Claire
    Daubin, Cedric
    Vanhille, Philippe
    Rondeau, Eric
    Palcoux, Jean-Bernard
    Mousson, Christiane
    Vigneau, Cecile
    Bonmarchand, Guy
    Guidet, Bertrand
    Galicier, Lionel
    Azoulay, Elie
    Rottensteiner, Hanspeter
    Veyradier, Agnes
    Coppo, Paul
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08): : 1181 - 1186
  • [5] Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura
    Cataland, Spero R.
    Kourlas, Peter J.
    Yang, Shangbin
    Geyer, Susan
    Witkoff, Leslie
    Wu, Haiwa
    Masias, Camila
    George, James N.
    Wu, Haifeng M.
    [J]. BLOOD ADVANCES, 2017, 1 (23) : 2075 - 2082
  • [6] Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab
    Chemnitz, J
    Draube, A
    Scheid, C
    Staib, P
    Schulz, A
    Diehl, V
    Söhngen, D
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) : 105 - 108
  • [7] A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab
    Clark, William F.
    Rock, Gail
    Barth, David
    Arnold, Donald M.
    Webert, Kathyrn E.
    Yenson, Paul R.
    Kelton, John G.
    Li, Lihua
    Foley, Steven R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (02) : 208 - 217
  • [8] Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura
    Eskazan, Ahmet Emre
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (11) : 1751 - 1756
  • [9] Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story
    Froissart, Antoine
    Veyradier, Agnes
    Hie, Miguel
    Benhamou, Ygal
    Coppo, Paul
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (09) : 659 - 665
  • [10] Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
    Froissart, Antoine
    Buffet, Marc
    Veyradier, Agnes
    Poullin, Pascale
    Provot, Francois
    Malot, Sandrine
    Schwarzinger, Michael
    Galicier, Lionel
    Vanhille, Philippe
    Vernant, Jean-Paul
    Bordessoule, Dominique
    Guidet, Bertrand
    Azoulay, Elie
    Mariotte, Eric
    Rondeau, Eric
    Mira, Jean-Paul
    Wynckel, Alain
    Clabault, Karine
    Choukroun, Gabriel
    Presne, Claire
    Pourrat, Jacques
    Hamidou, Mohamed
    Coppo, Paul
    [J]. CRITICAL CARE MEDICINE, 2012, 40 (01) : 104 - 111
1234